www.tickerreport.com ·
kamada nasdaqkmda issues quarterly earnings results misses expectations by 0 05 eps
Topic context
This topic has been covered 301408 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedKamada's earnings miss is company-specific, not sector-wide. The maintained guidance and new plasma center indicate no fundamental demand weakness for its products (KEDRAB, biosimilars). Commercial mechanism is weak: the miss is small and guidance unchanged, so no immediate margin or supply chain impact. The plasma center expansion may improve future revenue but is not yet material.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Kamada (NASDAQ: KMDA) reported Q1 2026 EPS of $0.07, missing consensus of $0.12 by $0.05.
- Revenue was $45.24 million, below expected $46.72 million.
- Full-year 2026 revenue guidance maintained at $200-205 million; adjusted EBITDA guidance $50-53 million.
- Company cited strong demand for KEDRAB and plans to expand biosimilars business.
- Commercial plasma sales from new FDA-approved San Antonio center expected in H2 2026.
Kamada's mid-term outlook for plasma-derived products and KEDRAB is expected to improve by 1-4 weeks; PHARMA_BIOTECH is affected up. Key risk: the maintained guidance may already price in the earnings miss.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid